ZEOXOTCBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Zeo ScientifiX, Inc.
Financials through Q2 FY2026, quarter ended Apr 30, 2026Last filing: 10-Q on Jun 15, 2026
$0.91+0.00 (+0.15%)
Close on Oct 19, 2026
- Market cap
- $7.08M
- P/E (TTM)
- –
- Dividend yield
- –
Zeo ScientifiX, Inc. revenue by segment
By business segment
| Revenue | TTM Q4 18 | TTM Q3 18 | TTM Q2 18 | TTM Q1 18 | TTM Q4 17 | TTM Q3 17 | TTM Q2 17 | TTM Q1 17 | TTM Q4 16 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient Referral and Product Sales [Member] | $964.53K | $865.10K | $912.55K | $959.99K | $569.85K | $312.47K | $197.18K | $123.87K | $184.88K | 100.0% | +69.3% |
| MMTC Activities [Member] | $0 | $0 | $0 | $0 | $0 | – | – | – | – | 0.0% | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Zeo ScientifiX's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.